Physicians’ Behavior and Their Interactions With Drug Companies: A Controlled Study of Physicians Who Requested Additions to a Hospital Drug Formulary

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 9, 1994, Pages 684-689

  Chren, Mary Margaret ^a   Landefeld, C Seth ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CEFIXIME; CICLOPIROX; CLOFAZIMINE; CLOZAPINE; DICLOFENAC; DILTIAZEM; DISOPYRAMIDE; ESMOLOL; FLUCONAZOLE; FLURBIPROFEN; FLUTAMIDE; GANCICLOVIR; IFOSFAMIDE; KETOROLAC; LEVAMISOLE; MEFLOQUINE; METHOXSALEN; MORACIZINE; NAFARELIN; NIMODIPINE; OCTREOTIDE; OMEPRAZOLE; PERGOLIDE MESILATE; PERMETHRIN; RECOMBINANT ERYTHROPOIETIN; SALBUTAMOL; SELEGILINE; TYPHOID VACCINE; UNINDEXED DRUG;

ARTICLE; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; PHARMACY; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0027972458     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510330062035     Document Type: Article

References (26)

1. Waud DR. Pharmaceutical promotions—a free lunch? N Engl J Med. 1992;327:351-353.
2. Bricker EM. Industrial marketing and medical ethics. N Engl J Med. 1989;320:1690-1692.
3. Cassel CK. Pharmaceutical promotions. N Engl J Med. 1992;327:1687.
4. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies, and gifts. JAMA. 1989;262:3448-3451.
5. Goldfinger SE. A matter of influence. N Engl J Med. 1987;316:1408-1409.
6. Katz AM. Pharmaceutical promotions. N Engl J Med. 1992;327:1687.
7. Kessler DA. Drug promotion and scientific exchange: the role of the clinical investigator. N Engl J Med. 1991;325:201-203.
8. Berman JL. Physicians and the pharmaceutical industry. Ann Intern Med. 1990;113:900.
9. Gorski TN. Doctors, drug companies, and gifts. JAMA. 1990;263:2177.
10. Wilkes MS, Shuchman M. Pitching doctors. New York Times Magazine. November 5, 1989:88-129.
11. Scarpinato L. Pharmaceutical sales representatives. J Gen Intern Med. 1991;6:181.
12. American Federation for Clinical Research. American Federation for Clinical Research guidelines for avoiding conflict of interest. Clin Res. 1990;38:239-240.
13. Abramowitz PW, Fletcher CV. Counterpoint: let's expand the formulary system and renew its vigor. Am J Hosp Pharm. 1986;43:2834-2838.
14. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982; 73:4-8.
15. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical sales representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990;5:240-243.
16. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA. 1990;264:1693-1697.
17. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Cont Educ Health Prof. 1988;8:13-20.
18. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest. 1992;102:270-273.
19. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius. 1986;6:66-69.
20. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co; 1986.
21. Yasuda SU, Woosley FL. The clinical value of FDA class C drugs approved from 1981 to 1988. Clin Pharmacol Ther. 1992;52:577-582.
22. ABMS Compendium of Certified Medical Specialists. 3rd ed. Evanston, Ill: American Board of Medical Specialties; 1990.
23. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1989;2.
24. Fleiss IL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981:64.
25. Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992;327:1135-1140.
26. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care. 1990;28:928-942.